Research Article

Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 Patients

Yi Song, Fengna Dou, Zhe Zhou, Ningmin Yang, Jing Zhong, Jie Pan, Qiqi Liu, Jianzhong Zhang, and Shengqi Wang

1 Beijing Institute of Radiation Medicine, Beijing, China
2 Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious Diseases, Beijing, China
3 Hangzhou Zhiyuan Medical Laboratory Co., Ltd., Hangzhou, China
4 Huzhou Central Hospital, Huzhou, China
5 Wenzhou Central Hospital, Wenzhou, China
6 State Key Laboratory of Infectious Disease Prevention and Control, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Chinese Center for Disease Control and Prevention, Beijing, China

Correspondence should be addressed to Qiqi Liu; liuqiqi@bmi.ac.cn, Jianzhong Zhang; zhangjianzhong@icdc.cn, and Shengqi Wang; sqwang@bmi.ac.cn

Received 1 May 2018; Revised 24 July 2018; Accepted 8 August 2018; Published 10 September 2018

Academic Editor: Mikihiro Fujiya

Copyright © 2018 Yi Song et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Helicobacter pylori (H. pylori) is one of the most frequent and persistent bacterial infections that affect nearly half of the world’s population. Antibiotic resistance is a constantly evolving process and local surveillance of antibiotic resistance is warranted to guide clinicians in their choice of therapy. The aim of this study was to establish a microarray-based detection to identify H. pylori infection, clarithromycin and levofloxacin susceptibility, and CYP2C19 genetic polymorphism and guide to potential choice of proton pump inhibitor (PPI), antibiotic administration for tailored H. pylori eradication therapy. Methods. By analyzing the sequence of human genomic CYP2C19∗2 and CYP2C19∗3 and mutations within the 23S rRNA and gyrA gene regions conferring clarithromycin and levofloxacin resistance, respectively, we developed a microarray for individual therapy detection of H. pylori infection. Plasmids were established as positive or limit of detection (LOD) reference materials. The specificity and sensitivity of the microarray had been performed. And a total of 1083 gastric biopsy samples were tested and the Kappa value had been calculated between the array and Sanger sequencing. We also analyzed the resistance to clarithromycin and levofloxacin in China, as well as the CYP2C19 polymorphisms. Results. The LOD of detecting H. pylori was 10⁵ CFU/mL and human genome DNA was 2 ng/µL. The detection results of 1083 gastric biopsy samples showed that 691 (63.80%) were H. pylori positive, of which 266 (38.49%) were resistant to clarithromycin, 192 (27.79%) were resistant to levofloxacin, and 61 (8.83%) were resistant to both of them. For the type of CYP2C19 polymorphism, 412 (38.04%) were homozogous fast type (HomEM), 574 (53%) were heterozygous EM (HetEM), and 97 (8.96%) were poor metabolizer (PM). Conclusions. The proposed microarray-based detection has high specificity, sensitivity, and reproducibility for detecting the resistance of clarithromycin or levofloxacin as well as CYP2C19 polymorphism, which may help to improve the clinical eradication rate of H. pylori.

1. Introduction

More than 50% of the world’s population is infected with Helicobacter pylori (H. pylori), and the rate of infection among Chinese adults is 40%-60% [1]. H. pylori infection is associated with a variety of gastrointestinal diseases such as gastritis, peptic ulcer and promotes the accumulation of various mutations and might promote gastric carcinogenesis [2].

At present, triple or quadruple therapy based on proton pump inhibitors (PPIs) combined with amoxicillin and clarithromycin (or metronidazole) is recognized as a first-line treatment of H. pylori. PPI-clarithromycin-amoxicillin with a bismuth quadruple regimen was recommended as the...
second-line after prior treatment failure in the Maastricht V/Florence Consensus Report [3] and the Fifth Chinese Consensus Report [1]. The efficacy of therapy is mainly affected by the following two factors: one hand is antibiotic resistance and primary drug-resistance rate of three out of six kinds of antibacterial drugs recommended by consensus report has raised, metronidazole (40%-70%), clarithromycin (20%-50%), and levofloxacin (20%-50%), and even multidrug resistance also occurred. The antibiotic resistance has significantly reduced the eradication rate [1, 4, 5]. Due to resistance, eradication rate of standard triple therapy has less than the 80%, and even the treatment time of standard triple therapy increased from 7d to 10d or 14d, and eradication rate can only improve about 5% [6]. Another hand is that PPI inhibitors pay an important role for the success of triple therapy. PPIs are serials of pharmaceutical agents that target H+ /K+-ATPase and have high potency to increase gastric pH value coupled with minor side effects, which made them very popular in gastrointestinal disorders, particularly in H. pylori infection eradication regimen [7]. PPIs high acid suppression make acid-labile antibiotics such as clarithromycin more stable by increasing gastric pH value, thereby increasing concentration and H. pylori sensitivity to antibiotics [8]. PPIs (except rabeprazole) are mainly metabolized by cytochrome P450 2C19 (CYP2C19), whose highly polymorphic genotype can cause variability response in omepazole- based or lansoprazole-based triple therapies [9]. CYP2C19*2 (681 G > A, rs4244285) and CYP2C19*3 (636 G > A, rs4986893) are most frequent variant and the two types alleles associated with loss of function [10].

According to CYP2C19*2 and CYP2C19*3, the CYP2C19 phenotype has been classified into three groups: homozygous extensive metabolizers (Hom-EMs), heterozygous extensive metabolizers (Het-EMs), and poor metabolizers (PMs) [12]. Research shows that, in the first-line treatment based on PPI, PM patients can get the highest remedial therapy based on PPIs, the H. pylori eradication rate. In remedial therapy based on PPIs, the H. pylori eradication rate between HomEM and HetEM is significantly different [7].

There are four most often observed point mutations associated with clarithromycin: A2144G, A2143G, A2142G, and A2143C in 23S rRNA [12]. “Hot-spots” (A2142G and A2143G, approximately 80% of all mutations) domain V has shown the major mechanism of clarithromycin resistance [11, 13]. Mutations at amino acid 87 (Asn to Lys, Tyr, or Ile) and/or 91 (Asp to Asn, Gly, or Tyr) in the quinolones resistance-determining region (QRDR) of gyrA weakened binding between the quinolone antibiotics and the gyrase, causing antibiotic resistance [14–16]. Mainly Asn-87-Lys and Asp-91-Gly were found in 92.8% (52/56) of the levofloxacin-resistant isolates [17].

In this study, we established a visual DNA microarray method to detect susceptibility of clarithromycin and levofloxacin, polymorphisms of CYP2C19 in patients simultaneously. After validating accuracy, specificity, and sensitivity of the microarray, we applied it in clinical research by detecting gastric mucosa samples of 1083 cases and assessed the antibiotic resistance of H. pylori and genetic polymorphism of CYP2C19 in China.

2. Materials and Methods

2.1. Specimen Collection and Processing. The gastric biopsy samples were collected from Chinese Center for Disease Control and Prevention (342), Chinese Huzhou Central Hospital (394), and Chinese Wenzhou Central Hospital (347), respectively. Of the subjects, 541 were male patients (49.95%) and 542 were females (50.05%), with ages ranging from 14 to 85 years. Subjects undergoing gastroscopy and sampling for diagnosis of upper gastrointestinal diseases were recruited. A total of 660 patients were positive for 13C/14C-urea breath test. Of these patients, 403 without a history of treatment for H. pylori infection and 257 had previously received H. pylori eradication therapy.

Gastric biopsy specimens were crushed or cut into pieces using a sterile glass homogenizer by the Full Automatic Tissue Grinding Instrument (Tuhe Mechatronics Co., Shanghai, China) and mixed with 200 μL normal saline. Total DNA mixtures from biopsy specimens were extracted using the QIAmp DNA Mini Kit (Qiagen, Hilden, Germany) following the protocol.

2.2. Multiplex PCR. DNA regions involved in clarithromycin (23S rRNA), quinolone (gyrA) resistance, CYP2C19*2 (681 G > A, rs4244285), and CYP2C19*3 (636 G > A, rs4986893) were amplified by PCR as previously reported [18–20]. Primers were picked in the conserved upstream or downstream regions and probes were designed at positions of mutations (Table 1). All the primers and probes were verified by BLAST (http://blast.ncbi.nlm.nih.gov/).

All reverse primers for target genes were labeled by biotin at the 5' -ends and multiplex PCR was performed in one tube. Reaction mixtures (25 μL) contained 12.5 μL of 2× Multiplex PCR Mix (cwBiotech, Beijing, China) and 3 μL of DNA template. The concentrations of forward and reverse primers all were 0.12 μM and 1.2 μM, respectively. PCR was performed on a Thermal Cycler PCR system (Applied Biosystems, Foster City, US) using the following conditions: 15 min at 95°C; 45 cycles of 30 s at 94°C, 60 s at 65°C, and 30 s at 72°C; and a final extension of 5 min at 72°C.

2.3. Construction of Reference Plasmids. The international standard strain H. pylori 26695 was used to construct the wild-type control plasmid and normal human genomic DNA was used as template for PCR amplification. Mutant control plasmids were constructed using PCR site-directed mutagenesis to amply fragments of mutations in specific sites. The purified amplification products were ligated with PGM-T vector and cloned into DH5α. The target fragments were identified by sequencing the entire regions. Then the positive clones were picked to culture. After the determination of the initial concentration, the bacterial liquid was diluted to 1 × 106, 1 × 105, 1 × 104, and 1 × 103 CFU/mL by using phosphate buffer saline. Plasmids of human genomic DNA were extracted and diluted to 10 ng/μL, 5 ng/μL, 2 ng/μL, and 1 ng/μL in order to determine the LOD of the microarray.
Table 1: The primer and probe sequences for microarray.

| Targeted gene | Primer/Probe | Sequencing (5'-3') |
|---------------|--------------|-------------------|
| **CYP450**    | 2CI92-F<sup>a</sup> | CAGAGCTTGCGCATATTGATCT |
|               | 2CI92-R<sup>b</sup> | GATCAGGAAGCAATCAATAAA |
|               | 2CI93-F       | GATCAGCAATTCTTTAATGGGTA |
|               | 2CI93-R       | TTCAAAAATGTACCTAGGGCTTGGG |
|               | 2CI92W        | ATTATTTCCGGGAACCAT |
|               | 2CI92M        | TTATTTCCAGGAACCCCAT |
|               | 2CI93W        | TAAGCACCCCTTGATGCAGGT |
|               | 2CI93M        | GATAACCCCCCTAGAATCCAGG |
| **23S rRNA**  | H. PYLORI23S-F | ATTCAGTGAAATTGTAGTGGAGGT |
|               | H. PYLORI23S-R | CCATTAGCAGTGCTAAGTTGGTA |
|               | 42W43W        | CCGCCAGAAGCGAAAGCCCA |
|               | 42M43W        | CCGGAAAGCAAGGAAGCCCA |
|               | 42W43M        | GGCAGCAGGAAGACCCCG |
|               | 42M43M        | GGCAGAGACGGGAGACCCCG |
| **gyrA**      | GF240         | GGGTGATGTGATTGGTAAATAC |
|               | GR319         | TCGAAAATCTTCGCCATTCTC |
|               | 87WT          | CCATGGCGATAATGGGTCTCA |
|               | 87WC          | CCATGGCGATAATGGGTCTCA |
|               | 87MA          | CCGGTTTATGGTCGCTAG |
|               | 87MG          | TCGGTTTATGGTCTGCTAG |
|               | 91W           | GCGGTTTATGGTCGCTAG |
|               | 91MG          | TCGGTTTATGGTCTGCTAG |
|               | 91MA          | TCGGTTTATGGTCTGCTAG |
| **Quality control** | H. PYLORI23S-F | ATTCAGTGAAATTGTAGTGGAGGT |
|               | H. PYLORI23S-R | CCATTAGCAGTGCTAAGTTGGTA |
|               | 2CI92-F<sup>a</sup> | CAGAGCTTGCGCATATTGATCT |
|               | 2CI92-R<sup>b</sup> | GATCAGGAAGCAATCAATAAA |
|               | 2CI93-F       | GATCAGCAATTCTTTAATGGGTA |
|               | 2CI93-R       | TTCAAAAATGTACCTAGGGCTTGGG |
|               | 2CI92W        | ATTATTTCCGGGAACCAT |
|               | 2CI92M        | TTATTTCCAGGAACCCCAT |
|               | 2CI93W        | TAAGCACCCCTTGATGCAGGT |
|               | 2CI93M        | GATAACCCCCCTAGAATCCAGG |
| **Quality control** | 2CI92-F<sup>a</sup> | CAGAGCTTGCGCATATTGATCT |
|               | 2CI92-R<sup>b</sup> | GATCAGGAAGCAATCAATAAA |
|               | 2CI93-F       | GATCAGCAATTCTTTAATGGGTA |
|               | 2CI93-R       | TTCAAAAATGTACCTAGGGCTTGGG |
|               | 2CI92W        | ATTATTTCCGGGAACCAT |
|               | 2CI92M        | TTATTTCCAGGAACCCCAT |
|               | 2CI93W        | TAAGCACCCCTTGATGCAGGT |
|               | 2CI93M        | GATAACCCCCCTAGAATCCAGG |

<sup>a</sup> F: forward primer; <sup>b</sup> R: reverse primer; reverse primers used for microarray have biotin conjugated at 5'-ends; <sup>c</sup> W: wild genotype probe; <sup>d</sup> M: mutant genotype probe, an oligonucleotide of 12 T's with an amino-labeled 3'-end was conjugated to the 3'-ends of all probes; <sup>e</sup> an oligonucleotide of 20 T's with an amino-labeled 3'-end, biotin-labeled 5'-end was used as microarray quality control.

2.4. Microarray Fabrication. A repeat sequence of 12T- with an amino labeled 3'-end was connected to the 3'-end of all the probes and fixed on the aldehyde-chip surface. All modified microarray probes were synthesized by Sangon Biotech Co., Ltd. (Shanghai). Probes, at 50 μM final concentration, were spotted thrice repeatedly by using a noncontact inkjet Nanoplotter 2.1 (GeSim, Dresden, Germany) on the aldehyde-chip after mixing with uniform proportional printing buffer (5% glycerol, 0.1% sodium dodecyl sulfate (SDS), 6× saline-sodium citrate buffer (SSC), and 10× Denhardt). Quality control (QC) probe was spotted eight times repeatedly in the horizontal direction at a final concentration of 12.5μM in order to manage the standard operation and calibrate the signal values. Each aldehyde slide was divided into 10 blocks (11×11 mm) by a waterproof film that can detect 10 different samples. The layout was shown in Figure 1(a) and the principle of hybridization was shown in Figure 1(b). The fabricated microarray was placed in a dryer for 24h at room temperature. By washing once with 0.2% SDS and once with distilled water for 30 s at room temperature, the unbound probes were removed before use.

2.5. Hybridization and Signal Detection. After amplification, the products were denatured at 95°C for 5 min and immediately placed on ice for 5 min and then mixed with 5 μL of hybridization buffer (8× SSC, 0.6% SDS, 10% formylamine, and 10× Denhardt). A total of 10 μL hybridization mixture were hybridized on the microarray in a hybrid-box for 45 min at 45°C. The slide was washed for 30 s successively in 1× SSC and 0.2% SDS, 0.2× SSC, and 0.1× SSC at room temperature. Then the chip was incubated with 15 μL of 25 nM streptavidin-quantum dots (StrQDs, Wuhan Jiayuan Quantum Dots Co., Ltd.) for 30 min at 37°C and washed with PBS-T (phosphate buffer, 0.05% Tween 20) five times for 20 s and distilled water once for 10 s at room temperature. Subsequently, 30 μL of aqueous silver acetate solution and hydroquinone citric acid solution (each 15 μL) mixture were added. When the black signal point appeared, the chip was washed with distilled water and dried to scan by Image Scanner (UMAX, Amersham Biosciences). The probe signal densities were calculated by Gel-Pro Analyzer Vision 4.0 (Media Cybernetics, Silver Spring, USA).

2.6. Confirmation by Sequencing and Statistical Analysis. All these 1083 gastric biopsy samples were characterized by PCR amplification and gel electrophoresis. PCR-amplified fragments were purified by using DNA purification Kit DP241 (Tiangen Biotech Beijing Co., Ltd.) and sequenced by the dideoxy chain termination method.
According to the sequencing results, the coincidence rate of the microarray results had been calculated. McNemar Chi-square test and Kappa consistency check were performed to identify the difference and consistency between the microarray and the sequence. The SPSS 17.0 software package (SPSS Inc. Chicago, USA) was used for all analyses.

3. Results

3.1. Determination of Threshold Signal Intensity. The signal intensities values were quantified by Gel-Pro analyzer and the signal intensities were calibrated as follows: the calibrated value of a probe = mean signal intensities value of the probe / mean signal intensities value of the QC probe (the same detection block) ×100.

For the two probes of CYP2C19*2, the ratio of the calibrated value of 2C19*2W to that of 2C19*2M was determined. If the ratio was greater than 2.0, the locus was considered to be wild type and homozygote, while if the ratio was less than 0.5, the loci were considered to be homozygous mutation. If the ratio was between 0.5 and 2.0, we determined this locus was heterozygous. Two probes of CYP2C19*3 (2C19*3W and 2C19*3M) criteria were the same as CYP2C19*2. For the four probes of 23S rRNA (42W43W, 42M43W, 42W43M, and 42M43M), the one of calibrated value two times greater than the other three ones was considered to be positive. Criteria of the four 87-locus probes (87WT, 87WC, 87MA, and 87MG) and three 91-locus probes (91W, 91MG, and 91MA) of gyrA were the same as 23S rRNA.

3.2. Specificity and Sensitivity of Microarray Test. To evaluate the specificity of the microarray method, we detected the reference plasmids. The result images covering 15 probes were shown in Figure 2 and showed that the microarray was able to exactly distinguish the mutation sites of these nucleotides. The negative control H. pylori 26695 showed the negative microarray results which also demonstrated the specificity of this assay (Figure 2).

To determine the absolute LOD of this strategy, serially diluted recombinant plasmids had been quantified by the copy numbers served as the reference materials (i.e., from \(1 \times 10^5\), \(1 \times 10^4\), \(1 \times 10^3\), and \(1 \times 10^2\) CFU/mL for plasmid bacteria and 10, 5, 2, and 1 ng/\(\mu\)L for human genomic DNA). The absolute LODs for the plasmids were 10^2 CFU/mL and...
Figure 2: Visible detection of CYP2C19*2, CYP2C19*3, 23S rRNA, and gyrA (positive and negative controls). (a) Wild genotype of CYP2C19*2 and CYP2C19*3. (b) Mutant genotype of CYP2C19*2 and CYP2C19*3. (c) Wild at position 2142 and 2143 of 23S rRNA, wild genotype T at Asn-87, and mutant genotype G at Asp-91 of gyrA. (d) Mutant at position 2142 and wild at position 2143 of 23S rRNA, wild genotype G at Asn-87 and wild genotype GA at Asp-91 of gyrA. (e) Wild at position 2142 and mutant at position 2143 of 23S rRNA, mutant genotype G at Asn-87, and wild genotype GA at Asp-91 of gyrA. (f) Mutant at position 2142 and wild at position 2143 of 23S rRNA, wild genotype T at Asn-87, and wild genotype GA at Asp-91 of gyrA. (g) Wild at position 2142 and 2143 of 23S rRNA, mutant genotype A at Asn-87, and mutant genotype AA at Asp-91 of gyrA. (h) Standard strain 26695 of H. pylori.

2 ng /µL for the human genomic DNA (Figure 3(a)). 23S rRNA and gyrA of H. pylori detection kit (PCR-Fluorescence Probing, provided by our laboratory) were also used to detect 23S rRNA and gyrA reference plasmids (1 × 10^5 to 1 × 10^6 copies/µL), respectively. The results of sensitivity comparison between microarray assay and real-time PCR showed that they had similar sensitivities (Figures 3(b) and 3(c)).

3.3. Detection of Human CYP2C19 Gene Polymorphism. The CYP2C19 polymorphic genotype in all 1083 patients was determined by microarray-based assay coupled with nucleotide sequencing. The results of the microarray showed that 412 cases (38%) were HomEM genotype for harboring two wild-type alleles on CYP2C19*2 and CYP2C19*3 loci. There were 574 cases (53%) that had one loss-of-function (LOF) variant allele in CYP2C19*2 or CYP2C19*3 that compromised the rates of PPI metabolism which were HetEM. PM carries two LOF variant alleles (CYP2C19*2 and CYP2C19*3) and 97 (9.0%) were PM in our study. Part of the microarray and sequencing results are shown in Figures 4 and 5. Compared with Sanger sequencing, the sensitivity, specificity, and concordance was 97.68%, 93.75%, and 93.94% for microarray detection of CYP2C19*2.

Table 2: Microarray and sequencing results of CYP2C19*2.

| CYP2C19*2 | Sequencing |
|-----------|------------|
| Microarray | AA AG/GA GG Total |
| AA        | 82 2 1 85 |
| AG/GA     | 6 507 29 542 |
| GG        | 1 450 456 |
| Total     | 89 514 480 1083 |

A sensitivity of 97.68%, specificity of 93.75%, positive predictive value of 93.94%, and negative predictive value of 98.68% for microarray detection of CYP2C19*2.

CYP2C19*2 and Kappa=0.884 (P < 0.0001) for CYP2C19*3, which revealed that the consistency between microarray and sequencing was statistically significant.

3.4. Detection of 23S rRNA and gyrA Mutations. Determined by sequencing, there were 691 cases as H. pylori positive and 266 cases that showed mutations of 23S rRNA. Part of the microarray and sequencing results are shown in Figure 6. The sensitivity, specificity, and concordance were 92.13%, 93.75%, and 95.94%, respectively, between the microarray and sequencing (Table 4). The performance of the two methods is not significantly different (chi-square = 5.897, P=1.000 > 0.05; Kappa value was 1.000, P < 0.0001).

For QRDR of the gyrA gene, 192 samples had point mutations in which 135 were at amino acid Asn-87 and amino acid Asp-91 were at codon 91. The sensitivity and
3.5. Correlation between H. pylori Mutations and CYP2C19 Genetic Polymorphism. Table 7 showed a correlation between the mutations of H. pylori and CYP2C19 genetic polymorphism. Chi-square test was used to assess differences and there was no significant correlation that was observed between CYP2C19 genetic polymorphism and mutations of 23S rRNA. (Z=23.323, P < 0.0001) at codon 91, indicating there is no statistical difference between the results of microarray and sequencing.
Figure 4: (a) CYP2C19*2 detection results of the microarray (indicating by yellow frame): A, B, and C were wild genotype GG; D, E, and F was heterozygous genotype AG/GA; G, H, and I were mutation genotype AA. (b) CYP2C19*2 detection results of sequencing (indicating by black frame): J was homozygous AA; K was heterozygous AG/GA; L was homozygous GG.

Figure 5: (A) CYP2C19*3 detection results of the microarray (indicating by yellow frame): a, b, and c were wild genotype GG; d, e, and f were heterozygous genotype AG/GA; g, h, and i were mutation genotype AA (B) CYP2C19*3 detection results of sequencing (indicating by black frame): j was homozygous AA (RC); k was heterozygous AG/GA (RC); l was homozygous GG (RC).
H. pylori to clarithromycin (P = 0.079) and levofloxacin (P=0.17).

4. Discussion

In China, prevalence of H. pylori strains resistance to clarithromycin, metronidazole, and levofloxacin (fluoroquinolone) has been increasing over the last decades. Studies show that clarithromycin resistance was higher than 10% and the success of standard eradication (first-line therapy) was less than 85% [18]. Many studies had confirmed that the eradication rate of clarithromycin sensitive strains was 87%-92%, while the eradication rate decreased to 18%-21% in clarithromycin resistant strains [19]. Levofloxacin was proposed as a salvage treatment regimen after the failure of clarithromycin-based treatments [20]. However, the frequency of levofloxacin resistance was widely recognized throughout the world, which may reduce the efficacy of levofloxacin-based therapeutic regimen [21, 22]. On the whole, the resistance rate of these antibiotics was very high in China; however, regional differences were exist. On the contrary, the resistance rates of H. pylori to amoxicillin...
Figure 7: (a) Microarray detection results of gyrA at Asn-87 (indicating by yellow frame): A, B, and C were wild genotype T/C; D, E, and F were mutation genotype A/G. (b) Sequencing results of gyrA at Asn-87 (indicating by black frame): J was wild genotype C, K was wild genotype T, L was mutation genotype A, and M was mutation genotype G.

Figure 8: (a) Microarray detection results of gyrA at Asp-91 (indicating by yellow frame): A, B, and C were wild genotype GA; D, E, and F were mutation genotype GG; G, H, and I were mutation genotype AA. (b) Sequencing results of gyrA at Asp-91 (indicating by black frame): J and K were wild genotype GA, L was mutation genotype AA, and M was mutation genotype GG.
Table 7: Correlation between H. pylori mutations and CYP2C19 genetic polymorphism.

| CYP2C19 polymorphism (cases) | Mutation rates (%) and cases (n) |
|-----------------------------|----------------------------------|
|                            | 23S rRNA                           | gyrA N87K  | gyrA D91G/ D91N |
| Hom-EMs (284)               | 2782 (79)                         | 19.01 (54) | 6.34 (18)       |
| Het-EMs (343)               | 30.90 (106)                       | 21.57 (74) | 9.91 (34)       |
| PMs (64)                   | 17.19 (11)                        | 15.63 (10) | 6.25 (4)        |
| P value                    | 0.079                             | 0.479      | 0.224           |

Hom-EMs: homozygous extensive metabolizers; Het-EMs: heterozygous extensive metabolizers; PMs: poor metabolizers

(0%~5%), tetracycline (0%~5%), and furazolidone (0%~1%) were still very low [23–25].

By assessing sensitivity of clarithromycin, levofloxacin, and genotypes of CYP2C19 before using the triple therapy, the choice of drugs for individual medication can ensure the success rate of treatment and reduce the overuse of antibiotics adverse reaction and waste of resources.

In this study, we designed specific probes to DNA regions involved in clarithromycin (23S rRNA), levofloxacin (gyrA) resistance, CYP2C19*2 (681G>A, rs4244285), and CYP2C19*3 (636G>A, rs4986893). The DNA microarray could be used to provide a type of antibiotics sensitivity of clarithromycin, levofloxacin, and polymorphisms of CYP2C19 before the patients’ treatment with triple or quadruple therapy. The microarray was fast so the entire experiment could be finished within 6 h from DNA extraction of samples to obtain visual results by naked eyes. The specificity and sensitivity of the microarray had been validated: the specificity concordance was 97.49% compared with the sequencing, and the sensitivity was 10^6 CFU/mL equivalent to fluorescence quantitative PCR (Figure 3).

DNA microarray technology was high throughput, efficiently, and low cost. Quantum dots served as a semiconductor nanocrystalline material due to their good fluorescence characteristics [23], which was widely used in bioimaging. Quantum dots acted as similar electron transfer and could convert a silver ion to a metallic silver atom in the presence of reductive reagents (such as hydroquinone). Silver atom deposited on the surface of quantum dots and could further catalyze the conversion of silver around. The cascade catalysis made silver particles accumulate together and form into silver shell, and then formation of black particles was visible by naked eyes. In this study we developed a new microarray visualization technology based on tyramine signal amplification coupled with quantum dot-catalyzed silver deposition (TSA-QDS) to detect and evaluate H. pylori resistance to clarithromycin or levofloxacin and the genotype of CYP2C19. The TSA-QDs possessed similar detection sensitivity as real-time PCR of 10^3 CFU/mL [26, 27] and the signal point of the method can be scanned by general scanners which are less expensive than fluorescence scanner. Without equipping sophisticated and expensive scanner, the microarray visualization technology greatly reduces the cost (less than six dollars per sample) of chip technology platform to popularize. Compared with traditional methods to detect gastric biopsy specimens such as phenotypic culture [28] and real-time PCR, the method was high throughput and accessible to detect coinfections with clarithromycin and/or levofloxacin-resistant and susceptible strains.

This study showed that distribution of CYP2C19 gene polymorphism in population from both Beijing in northern China and Zhejiang province in south eastern China was consistent with that of Chongqing in southwestern China [24] and Asia [7]. PMs and EMs accounted for a significant proportion in Asian population, while EMs accounted for one in Europeans [25]. CYP2C19 polymorphism could influence the PPIs metabolism and H^+ concentration in stomach and thus affect activity and stability of antibiotics. H. pylori was not completely destroyed or inhibited to grow by these antibiotics in the microenvironment, which might lead to microevolution of H. pylori even development of drug resistant strains [24]. Our study indicated that CYP2C19 genetic polymorphism was not significant associated with susceptibility of clarithromycin (P = 0.079) or levofloxacin (P=0.17); however there was a trend of correlation between CYP2C19 genotypes and clarithromycin resistance. When comparing the 23S rRNA mutations in CYP2C19 EMs and CYP2C19 PMs, the number of mutations was significantly higher in the CYP2C19 EM than in the CYP2C19 PM (P=0.037 < 0.05).

This study has some limitations. Firstly, the sequencing results of some samples were not consistent with the results of microarray detection. The false negative results of microarray may be due to the difference of the PCR amplification system. For microarray detection, all target genes were amplified in one tube while single PCR amplification was performed for sequencing, which may reduce the sensitivity of microarray detection. Secondly, the DNA microarray could not cover all genes of antibiotics for the eradication of H. pylori. Therefore, future studies could address the genes that account for antibiotic resistance of H. pylori.

5. Conclusions

In summary, we established a visible microarray-based detection that could simultaneously and specially determine the A2142G and A2143G mutation associated with clarithromycin, mutations at amino acids 87 and 91 in the levofloxacin, and human CYP2C19 genotype. The microarray-based detection was rapid, reliable, and high throughput and could be used easily for clinical applications in guidance of individual H. pylori eradication therapy.
Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

This clinical trial strictly adhered to the ethical standards of human medical research in the Declaration of Helsinki. This clinical trial used surplus samples after daily detection from Wenzhou Central Hospital, Huzhou Central Hospital, and Chinese Center for Disease Control and Prevention. All testing was out of touch with patients. All the results were only used as the raw data of this clinical trial and did not provide to the patients and did not serve for clinical diagnosis. There was no risk for patients. According to the “guidelines for clinical research technology of in vitro diagnostic reagents” issued by the China Food and Drug Administration, this clinical trial could not submit informed consent and ethical review.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Shengqi Wang, Jianzhong Zhang, Qiqi Liu, and Zhe Zhou conceived and designed the study. Yi Song, Fengna Dou, Qiqi Liu, and Zhe Zhou were responsible for the experimental analysis. Ningmin Yang, Jing Zhong, Jie Pan, and Jianzhong Zhang collected samples and provided clinical information. Yi Song wrote the paper and other coauthors contributed to the final draft. All authors read and approved the final manuscript.

Acknowledgments

Thanks are due to the team of Chinese Center for Disease Control and Prevention, Hangzhou Zhiyuan Medical Laboratory Co., Wenzhou Central Hospital, and Huzhou Central Hospital. This work was financially supported by the Major Laboratory Co., Wenzhou Central Hospital, and Huzhou Central Control and Prevention, Hangzhou Zhiyuan Medical Laboratory Co., Wenzhou Central Hospital, and Huzhou Central Hospital.

References

[1] G. Liu, J. Xie, Z. R. Lu et al., “Fifth Chinese national consensus report on the management of Helicobacter pylori infection,” Zhonghua Nei Ke Za Zhi, vol. 56, no. 7, pp. 523–545, 2017.
[2] T. Nishizawa and H. Suzuki, “Gastric carcinogenesis and underlying molecular mechanisms: helicobacter pylori and novel targeted therapy,” BioMed Research International, vol. 2015, Article ID 794378, 7 pages, 2015.
[3] P. Malfertheiner, F. Megraud, and C. O’Morain A, “Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report,” Gut, vol. 66, no. 1, pp. 6–30, 2017.
[4] M. M. Biernat, B. Iwańczak, A. Bińkowska, J. Grabińska, and G. Gościnia, “The prevalence of helicobacter pylori infection in symptomatic children: a 13-year observational study in the lower silesian region,” Advances in Clinical and Experimental Medicine, vol. 25, no. 2, pp. 303–308, 2016.
[5] P.-Y. Chen, M.-S. Wu, C.-Y. Chen et al., “Systematic review with meta-analysis: the efficacy of levofloxacin triple therapy as the first- or second-line treatments of Helicobacter pylori infection,” Alimentary Pharmacology & Therapeutics, vol. 44, no. 5, pp. 427–437, 2016.
[6] S. D. Georgopoulos, V. Papastergiou, and S. Karatapanis, “Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era,” Expert Opinion on Pharmacotherapy, vol. 16, no. 15, pp. 2307–2317, 2015.
[7] C.-H. Kuo, C.-Y. Lu, H.-Y. Shi et al., “CYP2C19 polymorphism influences Helicobacter pylori eradication,” World Journal of Gastroenterology, vol. 20, no. 43, pp. 16029–16036, 2014.
[8] Y.-A. Lin, H. Wang, Z.-J. Gu et al., “Effect of CYP2C19 gene polymorphisms on proton pump inhibitor, amoxicillin, and levofloxacin triple therapy for eradication of Helicobacter Pylori,” Medical Science Monitor, vol. 23, pp. 2701–2707, 2017.
[9] J. M. Shin and N. Kim, “Pharmacokinetics and pharmacodynamics of the proton pump inhibitors,” Journal of Neurogastroenterology and Motility, vol. 19, no. 1, pp. 25–35, 2013.
[10] A. Li-Wan-Po, T. Girard, P. Farndon, C. Cooley, and J. Lithgow, “Pharmacomgenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17,” British Journal of Clinical Pharmacology, vol. 69, no. 3, pp. 222–230, 2010.
[11] C.-H. Kuo, E.-C. Kuo, H.-M. Hu et al., “The optimal first-line therapy of Helicobacter pylori Infection in year 2012,” Gastroenterology Research and Practice, vol. 2012, Article ID 168361, 8 pages, 2012.
[12] X. Peng, Z. Song, L. He et al., “Gastric juice-based real-time PCR for tailored Helicobacter Pylori treatment: a practical approach,” International Journal of Medical Sciences, vol. 14, no. 6, pp. 595–601, 2017.
[13] M. Kargar, S. Ghorbani-Dalini, A. Doosti, and N. Souod, “Real-time PCR for Helicobacter pylori quantification and detection of clarithromycin resistance in gastric tissue from patients with gastrointestinal disorders,” Research in Microbiology, vol. 163, no. 2, pp. 109–113, 2012.
[14] T. Nishizawa, H. Suzuki, and T. Hibi, “Quinolone-based third-line therapy for Helicobacter pylori eradication,” Journal of Clinical Biochemistry and Nutrition, vol. 44, no. 2, pp. 119–124, 2009.
[15] T. Nishizawa, H. Suzuki, K. Kurabayashi et al., “Gatifloxacin resistance and mutations in gyrA after unsuccessful Helicobacter pylori eradication in Japan,” Antimicrobial Agents and Chemotherapy, vol. 50, no. 4, pp. 1538–1540, 2006.
[16] X. Teh, Y. Khoorsavi, W. C. Lee et al., “Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur,” PLoS ONE, vol. 9, no. 7, 2014.
[17] M. Mitifahussururur, A. F. Syam, I. A. Nusi et al., “Surveillance of Helicobacter pylori antibiotic susceptibility in Indonesia: different resistance types among regions and with novel genetic mutations,” PLoS ONE, vol. 11, no. 12, 2016.
[18] J.-M. Liou, M.-S. Wu, and J.-T. Lin, “Treatment of Helicobacter pylori infection: where are we now?” Journal of Gastroenterology and Hepatology, vol. 31, no. 12, pp. 1918–1926, 2016.
[19] M. Martos, L. Bujanda, Y. Salicio et al., “Clarithromycin for first-line treatment of Helicobacter pylori infection after culture in...
high-resistance regions,” European Journal of Gastroenterology & Hepatology, vol. 26, no. 12, pp. 1380–1384, 2014.

[20] G. Cammarota, R. Cianci, O. Cannizzaro et al., “Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection,” Alimentary Pharmacology & Therapeutics, vol. 14, no. 10, pp. 1339–1343, 2000.

[21] E. Glocker, H.-P. Stueger, and M. Kist, “Quinolone resistance in Helicobacter pylori isolates in Germany,” Antimicrobial Agents and Chemotherapy, vol. 51, no. 1, pp. 346–349, 2007.

[22] Y. Matsumoto, I. Miki, N. Aoyama et al., “Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan,” Digestive and Liver Disease, vol. 37, no. 11, pp. 821–825, 2005.

[23] C. G. Beckett, J. Tjaden, T. Burgess et al., “Evaluation of a prototype dengue-1 DNA vaccine in a Phase 1 clinical trial,” Vaccine, vol. 29, no. 5, pp. 960–968, 2011.

[24] R. Han, H. Lu, M.-W. Jiang et al., “Multicenter study of antibiotic resistance profile of H. pylori and distribution of CYP2C19 gene polymorphism in rural population of Chongqing, China,” Gastroenterology Research and Practice, vol. 2016, Article ID 8547686, 6 pages, 2016.

[25] I. Ieiri, T. Kubota, and A. Urae, “Pharmacokinetics of omeprazole (a substrate of CYP2C19) and comparison with two mutant alleles, CYP2C19*10 in exon 5 and CYP2C19*32 in exon 4, in Japanese subjects,” Clinical Pharmacology & Therapeutics, vol. 59, no. 6, pp. 647–653, 1996.

[26] D. Jin, H. Qi, S. Chen, T. Zeng, Q. Liu, and S. Wang, “Simultaneous detection of six human diarrheal pathogens by using DNA microarray combined with tyramide signal amplification,” Journal of Microbiological Methods, vol. 75, no. 2, pp. 365–368, 2008.

[27] Y. Zhang, Q. Liu, D. Wang, S. Chen, and S. Wang, “Simultaneous detection of oseltamivir- and amantadine-resistant influenza by oligonucleotide microarray visualization,” PLoS ONE, vol. 8, no. 2, 2013.

[28] J. Zhang, J. Zhong, J. Ding et al., “Simultaneous detection of human CYP2C19 polymorphisms and antibiotic resistance of Helicobacter pylori using a personalised diagnosis kit,” Journal of Global Antimicrobial Resistance, vol. 13, pp. 174–179, 2018.